TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Overview of attention for article published in Clinical Cancer Research, March 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 2 news outlets

twitter: 34 X users

Citations

dimensions_citation: 122 Dimensions

Readers on

mendeley: 134 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 40 X posts from 34 X users, with an upper bound of 73,017 followers.

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. https://t.co/asXJcYEpn1 https://t.co/zMScMp7FZR

28 May 2020

Reply Repost Favourite

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer https://t.co/M3KUipaqvV

22 May 2019

Reply Repost Favourite

https://t.co/30DF7AVvkE

26 Mar 2019

Reply Repost Favourite

RT @piet_ost: @MarkARubin1 @ASCO A comprehensive profiling of AR aberrations, CTCs and genomic markers have been assessed by @BramDL in htt…

26 Mar 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 36 additional X posts.